ReviewFrontiers in systems biology2026
Phosphorylation dynamics of sodium-independent organic anion transporter SLCO4A1 and its role in diseases: a review.
Review in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SLCO4A1, a membrane-localized organic anion transporter belonging to the solute carrier (SLC) family, mediates the sodium-independent transport of endogenous substrates, including steroid hormones, prostaglandins, and thyroid hormones. Despite increasing evidence supporting its physiological and pathological significance, a comprehensive review focusing on its phosphorylation landscape and phosphoregulation is currently lacking. Large-scale phosphoproteomic analyses have identified three predominant phosphorylation sites, T37, S40, and S43, within its N-terminal intrinsically disordered region, suggesting that phosphorylation is a potential regulator of SLCO4A1 localization, stability, and substrate specificity. Predicted upstream kinases, including MAPKs, CDKs, PAKs, and HIPK2, further link SLCO4A1 to signaling pathways governing cellular stress responses, inflammation, and cell-cycle progression. Aberrant expression of both SLCO4A1 and its antisense long non-coding RNA, SLCO4A1-AS1, has been reported in multiple malignancies, including colorectal, ovarian, lung, thyroid, and gastric cancers, where they are associated with poor clinical outcomes and activation of oncogenic signaling pathways. Beyond cancer, SLCO4A1 has also been implicated in inflammatory vascular disorders such as Behçet's disease and Kawasaki disease. This review comprehensively summarizes the structural organization, phosphoregulation, and disease relevance of SLCO4A1, with particular emphasis on phosphorylation as a central determinant of its transport activity and signaling functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.